DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

13 May 2024

Data from the first human study demonstrate excellent performance of Zerion Pharma’s Dispersome® technology

May 13, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces positive
results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a
pharmaceutical used to treat cystic fibrosis. The study was conducted by ZERION’s Spanish partner
Insud Pharma, a global leader in generic and branded pharmaceuticals.

The clinical study was a comparative oral bioavailability pilot study designed to assess the
pharmacokinetic parameters of two different Ivacaftor Dispersome® formulations relative to the
approved product Kalydeco® 150 mg film-coated tablets (Ivacaftor). Ivacaftor is formulated as a
polymeric amorphous solid dispersion in Kalydeco®


    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

    Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.